Previous close | 0.0100 |
Open | 0.0100 |
Bid | 0.0000 |
Ask | 0.0200 |
Strike | 110.00 |
Expiry date | 2024-06-21 |
Day's range | 0.0100 - 0.0100 |
Contract range | N/A |
Volume | |
Open interest | 57 |
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
GameStop shares continue their surge in May, a report says Arm Holdings seeks to launch its first artificial-intelligence chips next year, and Squarespace is being taken private in a deal valued at $6.9 billion.
Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.